Iol Chemicals & Pharmaceuticals Ltd. (BSE: 524164) is a Ludhiana, Punjab-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹6,016 Cr, it ranks #774 by market cap among the 6,197 Indian listed companies on FinBizNet, and #22 of 86 in Medicinal Chemicals and Botanical Products. At ₹202.24 (as of 16 Nov 2026), the share price is 9.7% below its 52-week high of ₹224.00 and 196.5% above its 52-week low of ₹68.21. The share price is up 122.4% over one year and up 21.4% over three months.
| Current Price | ₹202.24 |
|---|---|
| Market Cap | ₹6,016 Cr |
| BSE Code | 524164 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 43.9 |
| Return on Equity | 7.90% |
| Return on Assets | 4.77% |
| 52-Week Range | ₹68.21 – ₹224.00 |
| 1-Year Price Change | +122.4% |
| 3-Month Price Change | +21.4% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.49% |
| Headquarters | Ludhiana, Punjab |
| Website | www.iolcp.com |
| Revenue | ₹795 Cr |
|---|---|
| Net Profit | ₹65 Cr |
| Net Margin | 8.2% |
| EPS (Basic) | ₹2.21 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Iol Chemicals & Pharmaceuticals Ltd. reported revenue of ₹795 Cr in Q2 FY27, up 40.1% from ₹568 Cr in Q2 FY26 and up 5.1% from ₹756 Cr in Q1 FY27. It posted a net profit of ₹65 Cr for the quarter, against a net profit of ₹30 Cr in Q2 FY26 (up 117.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹528 Cr (Q4 FY25) to ₹795 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹795 Cr | ₹65 Cr | 8.2% |
| Q1 FY27 | ₹756 Cr | ₹64 Cr | 8.5% |
| Q4 FY26 | ₹619 Cr | ₹53 Cr | 8.6% |
| Q3 FY26 | ₹580 Cr | ₹21 Cr | 3.5% |
| Q2 FY26 | ₹568 Cr | ₹30 Cr | 5.3% |
| Q1 FY26 | ₹552 Cr | ₹34 Cr | 6.2% |
| Q4 FY25 | ₹528 Cr | ₹31 Cr | 6.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 62.28% of Iol Chemicals & Pharmaceuticals Ltd.'s shares as of Sept 2026, against 52.62% in Sept 2025 (+9.66 percentage points). Delivery averaged 32.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company operates through, Chemical and Pharmaceutical segments. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals a
1. Chemical-This segment produces and sells ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, para amino phenol, etc. 2. Pharmaceutical-This segment produces and sells various active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole, ursodeoxycholic acid, gabapentin, levetiracetam, paracetamol, etc. 3. Unallocable-0 4. Inter Segment Revenue-0
1. Pharmaceutical-59.7% 2. Chemical-49.6% 3. Unallocated-0.9%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Iol Chemicals & Pharmaceuticals Ltd. | ₹6,016 Cr | 43.9 | 7.90% | ₹795 Cr | +122.4% |
Listed by market capitalisation. Ratios are shown for context only.
Iol Chemicals & Pharmaceuticals Ltd. is trading at ₹202.24, with a market capitalisation of ₹6,016 Cr.
Iol Chemicals & Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Iol Chemicals & Pharmaceuticals Ltd. has a P/E of 43.9 and a return on equity of 7.90%.
Iol Chemicals & Pharmaceuticals Ltd. is listed on the BSE under the scrip code 524164.
Iol Chemicals & Pharmaceuticals Ltd.'s share price is up 122.4% over one year and up 21.4% over three months. Its 52-week range is ₹68.21 to ₹224.00.
In Q2 FY27, Iol Chemicals & Pharmaceuticals Ltd. reported revenue of ₹795 Cr and net profit of ₹65 Cr, with basic EPS of ₹2.21 (consolidated, parsed from the company's exchange filing).
Iol Chemicals & Pharmaceuticals Ltd. reported revenue of ₹795 Cr in Q2 FY27, up 40.1% from ₹568 Cr in Q2 FY26 and up 5.1% from ₹756 Cr in Q1 FY27.
Promoters held 62.28% of Iol Chemicals & Pharmaceuticals Ltd.'s shares as of Sept 2026, against 52.62% in Sept 2025 (+9.66 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.